February 28, 2014 — Lexmark’s Perceptive Software demonstrated its Universal Clinical Platform solution for enterprise clinical content management at the 2014 meeting of the Healthcare Information and Management Systems Society (HIMSS).

First Pediatric Patient Treated on Mevion S250 Proton Therapy System

February 28, 2014 — A 6-year-old with a highly malignant medulloblastoma brain tumor is the first pediatric patient treated using the Mevion S250 proton therapy system at Washington University Medical Center in St. Louis. This milestone event marks the first pediatric case ever treated on the world’s only single-room proton therapy system.

IBA (Ion Beam Applications S.A.), a provider of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announced the delivery of its 250th Blue Phantom. system in North America to Melbourne, Fla. 

HIMSS 2014 3rd Annual Analytics Mobile Survey PACS ECG Software Information Tech
HIMSS 2014 3rd Annual Analytics Mobile Survey PACS ECG Software Information Tech

HIMSS Analytics published the results of the third Annual HIMSS Analytics Mobile Survey at its annual conference in Orland, Fla. The survey examines use of mobile devices in provider patient care improvement initiatives. For the first time this year, the survey questions were modified to closely align with the six areas of the mHIMSS Roadmap, a strategic framework for providers to implement mobile and wireless technologies.

Visius Surgical Theatre

The U.S. Food and Drug Administration (FDA) cleared IMRIS Inc.’s upgraded Visius Surgical Theatre, which integrates Siemens' high-field MR scanners. The core imaging technology based on Siemens Aera 1.5T(tesla) and Skyra 3.0T technology helps IMRIS deliver better image quality with higher signal-to-noise ratio. It also provides faster 3-D image acquisition and improved ease-of-use and workflow during neurosurgical procedures using intraoperative MRI (iMRI).

Using portable ultrasound as a first-line imaging study in kids with suspected appendicitis helps reduce emergency room length of stay and reduces the need for CT scans, according to a team of Mount Sinai researchers. Point-of-care ultrasonography has a specificity of about 94 percent. Results from the study were published online Feb. 10 in the peer-reviewed journal Academic Emergency Medicine.

The U.S. Food and Drug Administration (FDA) recently granted 510(k) clearance to Siemens Healthcare for the Ysio Max, a digital radiography (DR) system offering Multiple Advances in X-ray (MAX), including time-saving user support features and X-ray detectors.

Navidea Biopharmaceuticals Inc. is a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals. It announced the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) and granted a Priority Review for the expanded use of Lymphoseek (technetium 99m tilmanocept) Injection indicated for sentinel lymph node (SLN) detection in patients with head and neck cancer. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a June 16 target review date for the Lymphoseek sNDA. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now